Robert Veltri
18Patents
10h-index
16Co-inventors
69Inventor score
Filing activity: Jul 22, 1983 → Feb 12, 2007
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6025128A | Prediction of prostate cancer progression by analysis of selected predictive parameters | Emerging Cross-Sectional Technologies | 177 | Expired |
| US5882864A | Biomarkers and targets for diagnosis, prognosis and management of prostate disease | Chemistry; Metallurgy | 135 | Expired |
| US4963364A | Microencapsulated antitumor agent | Human Necessities | 77 | Expired |
| US6463438B1 | Neural network for cell image analysis for identification of abnormal cells | Physics | 72 | Expired |
| US6218529A | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer | Chemistry; Metallurgy | 70 | Expired |
| US6190857A | Diagnosis of disease state using MRNA profiles in peripheral leukocytes | Physics | 39 | Expired |
| US5989811A | Sextant core biopsy predictive mechanism for non-organ confined disease status | Emerging Cross-Sectional Technologies | 36 | Expired |
| US4617262A | Assaying for circulating immune complexes with labeled protein A | Emerging Cross-Sectional Technologies | 14 | Expired |
| US6369195B1 | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer | Emerging Cross-Sectional Technologies | 10 | Expired |
| US5856112A | Method for selectively inducing biomarker expression in urologic tumor tissue for diagnosis and treatment thereof | Chemistry; Metallurgy | 10 | Expired |
| US5102909A | Pharmaceutically useful furyl substituted dihydroxyethylbutyrolactones | Chemistry; Metallurgy | 6 | Expired |
| US4883808A | Condensation products of cyclic diketones and ascorbic acid as immunomodulatory agents | Chemistry; Metallurgy | 5 | Expired |
| US4883813A | Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones | Human Necessities | 4 | Expired |
| US4518611A | 2-Furylbutyrolactone modulation of the immune system in mammals | Chemistry; Metallurgy | 2 | Expired |
| US7993830B2 | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer | Emerging Cross-Sectional Technologies | 1 | Active |
| US5098933A | Pharmaceutically useful Michael addition products of unsaturated aldehydes and ketones and ascorbic acid | Chemistry; Metallurgy | 1 | Expired |
| US7332270B1 | Diagnosis of disease state using mRNA profiles in peripheral leukocytes | Physics | 1 | Expired |
| US6156515A | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer | Emerging Cross-Sectional Technologies | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.